Nathan Jessop

Germany has shifted from relative pricing freedom to a market that is sensitive and influenced by cost-containment policies. But pharma is pressuring the country to change its policy again.

The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.